Arcutis Biotherapeutics prices public offering of 32.5M shares and pre-funded warrants for ~$93.5M net

Arcutis Biotherapeutics, Inc.

Offering: 32.5M common shares at $2.50 each plus pre-funded warrants for 7.5M shares at $2.4999 each.
Net proceeds expected ~$93.5M after discounts and expenses; closing expected October 24, 2023.
Underwriters granted 30-day option to purchase up to 6M additional common shares.
Pre-funded warrants have $0.0001 exercise price and include 9.99% beneficial ownership limitation (adjustable to 19.99%).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.